Wide Ranks

CINGW

Cingulate Inc. Warrants

0.0350

Top Statistics
Market Cap 0.0000 Forward PE 0.0000 Revenue Growth 0.00 %
Current Ratio 7.35 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 10 M Total Cash Per Share 5.68 Total Debt 234174
Total Debt To Equity 1.95 Current Ratio 7.35 Book Value Per Share 6.82
All Measures
Message Board Id finmb_1674914781 Return On Equity -2.74 City Kansas City
Uuid f7c67ac8-333f-38a6-9df5-ebbbcb08bc47 Previous Close 0.0350 Book Value 6.82
Total Debt 234174 Volume 8454 Price To Book 0.0051
Fifty Two Week Low 0.0315 Total Cash Per Share 5.68 Max Age 86400
Sand P52 Week Change 0.3133 Net Income To Common -16348455 Trailing Peg Ratio None
Total Cash 10 M Trailing PE 0.0000 Regular Market Previous Close 0.0350
Target Low Price 0.0000 Gmt Off Set Milliseconds -18000000 Open 0.0315
Free Cashflow -10794803 State KS Dividend Yield 0.00 %
Return On Assets -1.04 Time Zone Short Name EST Trailing Eps -1.73
Day Low 0.0315 Address1 1901 West 47th Place Target High Price 0.0000
Price Hint 4 Website https://www.cingulate.com Forward Eps 0.0000
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 651.00 %
Is_sp_500 False Regular Market Day High 0.0350 Profit Margins 0.00 %
Debt To Equity 1.95 Fifty Two Week High 0.0350 Day High 0.0350
Regular Market Open 0.0315 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Operating Cashflow -16934228 Currency USD
Time Zone Full Name America/New_York Is_nasdaq_100 False Market Cap 0.0000
Zip 66205 Quote Type EQUITY Industry Biotechnology
Long Name Cingulate Inc. Regular Market Day Low 0.0315 Current Price 0.0350
Financial Currency USD Current Ratio 7.35 Industry Disp Biotechnology
Country United States Float Shares 1 M Forward PE 0.0000
Regular Market Volume 8454 Ebitda -15568522 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States.

The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.

It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety.

The company was founded in 2012 and is headquartered in Kansas City, Kansas.